[go: up one dir, main page]

DE69706825D1 - Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen - Google Patents

Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen

Info

Publication number
DE69706825D1
DE69706825D1 DE69706825T DE69706825T DE69706825D1 DE 69706825 D1 DE69706825 D1 DE 69706825D1 DE 69706825 T DE69706825 T DE 69706825T DE 69706825 T DE69706825 T DE 69706825T DE 69706825 D1 DE69706825 D1 DE 69706825D1
Authority
DE
Germany
Prior art keywords
papillomavirus
pharmaceutical composition
infections caused
composition against
against tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69706825T
Other languages
English (en)
Other versions
DE69706825T3 (de
DE69706825T2 (de
Inventor
Jean-Marc Balloul
Nadine Bizouarne
Marie-Paule Kieny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69706825(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene SA filed Critical Transgene SA
Publication of DE69706825D1 publication Critical patent/DE69706825D1/de
Application granted granted Critical
Publication of DE69706825T2 publication Critical patent/DE69706825T2/de
Publication of DE69706825T3 publication Critical patent/DE69706825T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69706825T 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen Expired - Lifetime DE69706825T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9609584 1996-07-30
FR9609584A FR2751879B1 (fr) 1996-07-30 1996-07-30 Composition pharmaceutique contre les tumeurs et infections a papillomavirus
PCT/FR1997/001412 WO1998004705A1 (fr) 1996-07-30 1997-07-29 Composition pharmaceutique contre les tumeurs et infections a papillomavirus

Publications (3)

Publication Number Publication Date
DE69706825D1 true DE69706825D1 (de) 2001-10-25
DE69706825T2 DE69706825T2 (de) 2002-05-02
DE69706825T3 DE69706825T3 (de) 2006-08-24

Family

ID=9494633

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69706825T Expired - Lifetime DE69706825T3 (de) 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
DE69728914T Expired - Lifetime DE69728914T2 (de) 1996-07-30 1997-07-29 Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69728914T Expired - Lifetime DE69728914T2 (de) 1996-07-30 1997-07-29 Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen

Country Status (12)

Country Link
EP (2) EP1149910B1 (de)
JP (2) JP4070815B2 (de)
AT (2) ATE265535T1 (de)
AU (1) AU736720B2 (de)
CA (1) CA2234263C (de)
DE (2) DE69706825T3 (de)
DK (2) DK1149910T3 (de)
ES (2) ES2163795T5 (de)
FR (1) FR2751879B1 (de)
HK (1) HK1043809B (de)
PT (2) PT1149910E (de)
WO (1) WO1998004705A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
WO2000000217A1 (fr) * 1998-06-26 2000-01-06 Aventis Pasteur Immunisation a ciblage mucosal
BRPI0712158B8 (pt) * 2006-06-20 2021-05-25 Transgene Sa processo para produzir uma composição de poxvírus de tipo selvagem, atenuado e/ou recombinante sem especificidade de infecção visada
PT2382474E (pt) 2009-01-20 2015-06-03 Transgene Sa Icam-1 solúvel como biomarcador para a previsão de uma resposta terapêutica
BRPI1009892A2 (pt) 2009-03-24 2016-03-15 Transgène S A método ex-vivo para avaliar a eficácia de um tratamento em um paciente, e, kit para testar se um paciente está respondendo terapeuticamente a um método de tratamento compreendendo administração de uma composição imunogênica
SG175060A1 (en) 2009-04-17 2011-11-28 Transgene Sa Biomarker for monitoring patients
CN102740881A (zh) 2009-05-12 2012-10-17 特兰斯吉恩股份有限公司 正痘病毒产生和纯化方法
CA2767458A1 (en) 2009-07-10 2011-01-13 Bruce Acres Biomarker for selecting patients and related methods
RU2012106760A (ru) 2009-07-21 2013-08-27 Трансген Са Ферментативная композиция для ферментативного расщепления куриного эмбриона
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
AU2015357225B2 (en) 2014-12-01 2020-04-09 Transgene Sa Stable liquid vaccinia virus formulations
FR3042121A1 (fr) * 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018210804A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3111273C (en) 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
EP4117722A1 (de) 2020-03-12 2023-01-18 Bavarian Nordic A/S Zusammensetzungen zur verbesserung der pockenvirusstabilität

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
KR910016343A (ko) † 1990-03-20 1991-11-05 스타인, 부그 사람 파필로마바이러스(hpv) 16 단백질의 혈청반응성 에피토프
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DK0595935T3 (da) * 1991-07-19 2003-07-21 Csl Ltd Papillomavirusvaccine
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
CA2201592A1 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique

Also Published As

Publication number Publication date
AU3855297A (en) 1998-02-20
EP0862634A1 (de) 1998-09-09
DE69728914T2 (de) 2005-04-07
DE69706825T3 (de) 2006-08-24
EP1149910A1 (de) 2001-10-31
ES2163795T3 (es) 2002-02-01
DE69706825T2 (de) 2002-05-02
JP2000500662A (ja) 2000-01-25
FR2751879B1 (fr) 1998-10-30
ATE265535T1 (de) 2004-05-15
AU736720B2 (en) 2001-08-02
HK1043809B (zh) 2004-12-03
DK0862634T4 (da) 2006-05-08
WO1998004705A1 (fr) 1998-02-05
EP0862634B2 (de) 2006-03-01
CA2234263A1 (fr) 1998-02-05
CA2234263C (fr) 2009-10-13
DE69728914D1 (de) 2004-06-03
JP2007254474A (ja) 2007-10-04
PT1149910E (pt) 2004-09-30
DK1149910T3 (da) 2004-08-02
DK0862634T3 (da) 2002-01-21
JP4198735B2 (ja) 2008-12-17
JP4070815B2 (ja) 2008-04-02
HK1043809A1 (en) 2002-09-27
EP0862634B1 (de) 2001-09-19
EP1149910B1 (de) 2004-04-28
ES2215805T3 (es) 2004-10-16
PT862634E (pt) 2002-03-28
ATE205881T1 (de) 2001-10-15
FR2751879A1 (fr) 1998-02-06
ES2163795T5 (es) 2006-07-16

Similar Documents

Publication Publication Date Title
DE69706825D1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
TR199801179T2 (xx) Yeni taksoitler, bunlar�n haz�rlanmalar� ve ila� bile�imleri.
SE9504661D0 (sv) New compounds
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
ATE135700T1 (de) Substituierte biphenylpyridone als angiotensin ii antagonisten
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
RU95106674A (ru) Полиеновые соединения, фармацевтическая и косметическая композиция на их основе
FI891361A0 (fi) Menetelmä farmaseuttisesti vaikuttavien aryylihydratsonien valmistamiseksi
KR860005636A (ko) 활성성분으로 스페르구알린(Spergualin)을 함유하는 주사제 조성물과 그 제조방법.
UA50808C2 (uk) Композиція для лікування респіраторного дистрес-синдрому дорослих або респіраторного дистрес-синдрому новонароджених
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
RU94043771A (ru) Замещенные бензимидазольные соединения, способ лечения, фармацевтическая композиция и способ получения бензимидазольных соединений
NO971625L (no) Nye peptider med immunomodulatoriske effekter
EP0932613A4 (de) Expressionsblockierung von virulenten faktoren in s. aureus
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
CS156792A3 (en) Substituted diaminophthalimides and compounds analogous thereto
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
BR1100143A (pt) Composto, e, composição farmacêutica.
CA2111083A1 (en) Novel peptides, their preparation and use
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
RU95106653A (ru) Производные 2-имидазолин-5-онов и 2-имидазолин-5-тионов и фунгицидные композиции на их основе
CA2027814A1 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings